ARTICLE | Clinical News

ChronVac-C: Phase I/II data

December 7, 2009 8:00 AM UTC

Data from a Phase I/II trial showed that 3 of 6 patients who received the high dose (1,500 µg ) of ChronVac-C had transient reductions in serum levels of HCV RNA of up to 2.4log10, with immune respons...